The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

Department of Medical Oncology, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK.
Lung Cancer (Impact Factor: 3.96). 06/2008; 63(1):94-7. DOI: 10.1016/j.lungcan.2008.04.001
Source: PubMed


Malignant pleural mesothelioma (MPM) is a rapidly progressive invariably lethal tumor. Treatment options remain limited and the outcome in relapsed disease is poor warranting new therapeutic options. Following our previous experience in the first-line setting, we conducted a phase 2 open-label non-comparative study to assess the safety and efficacy of weekly vinorelbine chemotherapy, each cycle consisting of 30 mg/m(2) for 6 weeks, in patients with previous exposure to chemotherapy. In 63 individuals with relapsed MPM who had not received previous vinorelbine, we observed an objective response rate of 16% and an overall survival of 9.6 months (95% confidence interval 7.3-11.8 months). The main grade III/IV toxicity observed was neutropenia and toxicity was similar to weekly vinorelbine when used in the first-line setting. Weekly vinorelbine appeared to have a reasonable response rate with an acceptable toxicity profile in the second-line treatment of MPM. Its use should be prospectively evaluated in a randomised trial in the first or second-line therapy of MPM.

65 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant pleural mesothelioma is a neoplasm characterized by an increasing incidence and poor prognosis. When surgical treatment cannot be performed, systemic chemotherapy remains the main therapeutic option. Here we report the case of a 41-year-old female patient with epithelioid malignant pleural mesothelioma who was treated with carboplatin and pemetrexed despite her critical condition. She showed an impressive response to this first-line chemotherapy and, after disease progression, to further chemotherapy with gemcitabine and vinorelbine. She is still alive, with unexpectedly long-lasting survival.
    Tumori 11/2010; 96(6):1031-4. · 1.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Chemotherapie ist essenzieller Bestandteil sowohl kurativer als auch palliativer Behandlungskonzepte beim malignen Pleuramesotheliom (MPM). Bei der Mehrzahl der Patienten sind aufgrund des Ausbreitungsgrads der Erkrankung, ihres Alters bzw. vorhandener Komorbiditäten nur palliative Behandlungsoptionen möglich. Standard in der Erstlinientherapie ist die Kombination von Pemetrexed und Cisplatin, die zu einer signifikanten Verlängerung des Überlebens sowie zur Verbesserung der Lebensqualität bei gebesserter Lungenfunktion und tumorbedingter Symptome führt. Mit zunehmender Detektion molekularer Besonderheiten des MPM wächst die Zahl zielgerichteter Substanzen, die erfolgversprechend in Studien geprüft werden. Die Strahlentherapie spielt in der palliativen Behandlung des MPM eine untergeordnete Rolle. Der Stellenwert einer prophylaktischen Stich- oder Drainagekanalbestrahlung ist nicht geklärt. Die Talkumpleurodese zur Beseitigung ausgedehnter, rezidivierender Pleuraergüsse und eine kombinierte analgetische Behandlung sind feste Bestandteile des palliativen Managements beim MPM. Dieser Artikel gibt einen Überblick über Standards in der medikamentösen, insbesondere der palliativen systemischen Therapie des MPM, neue Substanzen und symptomorientierte Behandlungsoptionen. Chemotherapy is an essential part not only for curative but also for palliative treatment concepts for malignant pleural mesothelioma (MPM). For the majority of patients with MPM palliative forms of treatment are the only option due to the extent of the disease, their age or the presence of comorbidities. The standard first line chemotherapy is the combination of pemetrexed and cisplatin which not only leads to a significant extension of survival but also to an improvement of quality of life with better lung function and reduction of tumor-linked symptoms. With increasing detection of molecular characteristics of MPM the number of targeted agents increases which show promising results in trials. Radiotherapy plays a subordinate role in the palliative treatment of MPM. The significance of prophylactic radiation of puncture or drainage canals has not been clarified. Talc pleurodesis for the elimination of extensive, relapsing pleural effusion and a combined analgetic treatment are integral components of the palliative management of MPM. This article provides an overview of standards in medicinal, especially palliative systematic therapy of MPM, new substances and symptom-oriented treatment options.
    Der Pneumologe 01/2009; 7(1):36-42. DOI:10.1007/s10405-009-0351-z
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant pleural mesothelioma continues to challenge clinicians and scientists, since its incidence is rising and prognosis is far from favorable. Currently, the standard treatment consists of a combination of cisplatin and pemetrexed. The role of surgery and multimodality treatment remains controversial, while new treatment approaches, such as immunotherapy and targeted therapies, ad promising and interesting options. This review provides a comprehensive evaluation of emerging therapies and predictive biomarkers that are being tested.
    06/2012; 1(2). DOI:10.1007/s13665-012-0010-4
Show more